Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Servier Pharmaceuticals LLC
Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio
June 26, 2026
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
June 25, 2026
Promising Phase 1 Data for Servier’s Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
June 1, 2026
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
June 1, 2026
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
May 22, 2026
Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
May 12, 2026
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
May 11, 2026